

# Niels W C J Van De Donk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5958490/publications.pdf>

Version: 2024-02-01

133  
papers

9,201  
citations

46984

47  
h-index

43868

91  
g-index

134  
all docs

134  
docs citations

134  
times ranked

7798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1207-1219.	13.9	948
2	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood, 2016, 128, 384-394.	0.6	697
3	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	0.6	686
4	Multiple myeloma. Lancet, The, 2021, 397, 410-427.	6.3	349
5	CD38 antibodies in multiple myeloma: back to the future. Blood, 2018, 131, 13-29.	0.6	329
6	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, 2016, 128, 959-970.	0.6	286
7	Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond. Immunological Reviews, 2016, 270, 95-112.	2.8	280
8	CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Frontiers in Immunology, 2018, 9, 2134.	2.2	212
9	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 2017, 25, 1946-1958.	3.7	197
10	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 2016, 127, 681-695.	0.6	179
11	The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood, 2004, 103, 4362-4364.	0.6	171
12	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances, 2017, 1, 2105-2114.	2.5	155
13	Teclistamab, a B-cell maturation antigenâ€”â€”CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet, The, 2021, 398, 665-674.	6.3	138
14	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clinical Cancer Research, 2015, 21, 2802-2810.	3.2	136
15	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, 101, 616-625.	1.7	136
16	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136
17	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research, 2017, 23, 7498-7511.	3.2	134
18	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica, 2014, 99, 984-996.	1.7	124

#	ARTICLE	IF	CITATIONS
19	Highâ€Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 279-289.	1.1	117
20	Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood, 2003, 102, 3354-3362.	0.6	114
21	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	1.7	110
22	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptorâ€engineered T Cells. Clinical Cancer Research, 2019, 25, 4014-4025.	3.2	110
23	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	3.3	109
24	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs, 2018, 78, 19-37.	4.9	108
25	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica, 2015, 100, 263-268.	1.7	96
26	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, e100-e103.	1.7	90
27	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood, 2019, 134, 668-677.	0.6	87
28	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	1.7	86
29	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	3.3	81
30	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 2022, 36, 1371-1376.	3.3	81
31	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	3.3	79
32	CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematology,the, 2021, 8, e446-e461.	2.2	75
33	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematology,the, 2020, 7, e447-e455.	2.2	74
34	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 2022, 12, 32.	2.8	73
35	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	3.3	68
36	Immunomodulatory effects of CD38-targeting antibodies. Immunology Letters, 2018, 199, 16-22.	1.1	68

#	ARTICLE	IF	CITATIONS
37	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <i>Leukemia</i> , 2021, 35, 573-584.	3.3	67
38	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
39	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.	3.4	66
40	Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1105-9.	1.4	65
41	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	1.7	63
42	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. <i>PLoS ONE</i> , 2018, 13, e0197349.	1.1	60
43	Preclinical activity and determinants of response of the GPRC5D $\times$ CD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	2.5	56
44	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	3.3	55
45	Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. <i>Haematologica</i> , 2020, 105, e302-e306.	1.7	53
46	Preclinical Activity of JNJ-7957, a Novel BCMA $\times$ CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. <i>Clinical Cancer Research</i> , 2020, 26, 2203-2215.	3.2	53
47	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2016, 128, 2297-2306.	0.6	49
48	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 160-167.	1.7	49
49	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. <i>Science Translational Medicine</i> , 2021, 13, eab1962.	5.8	49
50	Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 5591-5601.	3.2	48
51	Immunotherapy in myeloma: how far have we come?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882266.	1.1	47
52	A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) $\times$ CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 40-41.	0.6	46
53	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
54	Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 1362.	1.3	45

#	ARTICLE	IF	CITATIONS
55	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. <i>Haematologica</i> , 2018, 103, e368-e371.	1.7	43
56	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
57	Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 110-122.	0.7	41
58	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021, 2, 302-318.	2.6	40
59	Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. <i>Clinical Cancer Research</i> , 2003, 9, 5735-48.	3.2	39
60	Targeted Therapy With Immunoconjugates for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1155.	2.2	38
61	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	4.9	34
62	Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. <i>Haematologica</i> , 2016, 101, e339-e342.	1.7	34
63	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
64	New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. <i>Current Pharmaceutical Design</i> , 2006, 12, 327-340.	0.9	31
65	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 197-206.	1.3	30
66	Resistance Mechanisms towards CD38 <sup>+</sup> -Directed Antibody Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1195.	1.0	28
67	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. <i>Clinical Cancer Research</i> , 2021, 27, 3793-3803.	3.2	27
68	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
69	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 599-609.	0.3	26
70	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492.	2.2	25
71	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021, 106, 1725-1732.	1.7	25
72	Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1096.	1.8	25

#	ARTICLE	IF	CITATIONS
73	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2758-2767.	0.8	25
74	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
75	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. <i>Cancers</i> , 2020, 12, 3713.	1.7	23
76	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. <i>Oncotarget</i> , 2020, 11, 4076-4081.	0.8	23
77	Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. <i>Leukemia</i> , 2020, 34, 1964-1966.	3.3	22
78	Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. <i>Haematologica</i> , 2021, 106, 2257-2260.	1.7	22
79	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
80	Efficacy and safety of daratumumab combined with all- <i>trans</i> retinoic acid in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5128-5139.	2.5	22
81	Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1571.	1.7	21
82	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. <i>Haematologica</i> , 2020, 105, 2879-2882.	1.7	20
83	Diagnosis and Risk Stratification in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 791-813.	0.9	19
84	Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e9-e11.	0.2	19
85	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. <i>Haematologica</i> , 2020, 105, 1650-1659.	1.7	19
86	Comparison of CD38 antibodies &lt;i>in vitro</i> and &lt;i>ex vivo</i> mechanisms of action in multiple myeloma. <i>Haematologica</i> , 2021, 106, 2004-2008.	1.7	19
87	Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. <i>Clinical Cancer Research</i> , 2005, 11, 429-39.	3.2	19
88	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 475-479.	1.2	18
89	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	0.6	18
90	Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2014, 99, 1846-1853.	1.7	17

#	ARTICLE	IF	CITATIONS
91	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 34009-34021.	0.8	17
92	CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100022.	2.0	16
93	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , 2020, 9, 378.	1.8	16
94	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	1.2	16
95	Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. <i>European Journal of Haematology</i> , 2016, 97, 479-488.	1.1	15
96	Reprint of "Immunomodulatory effects of CD38-targeting antibodies". <i>Immunology Letters</i> , 2019, 205, 71-77.	1.1	14
97	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1963-1971.	1.4	14
98	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. <i>Blood</i> , 2019, 134, 695-695.	0.6	14
99	Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. <i>Blood</i> , 2019, 134, 3106-3106.	0.6	14
100	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	0.8	13
101	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2020, 105, e80-e83.	1.7	12
102	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. <i>HemaSphere</i> , 2021, 5, e561.	1.2	11
103	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 2452.	1.7	11
104	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4593.	1.0	11
105	Sequencing multiple myeloma therapies with and after antibody therapies. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 248-258.	0.9	10
106	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. <i>Blood</i> , 2019, 134, 137-137.	0.6	10
107	Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 33621-33622.	0.8	10
108	Carfilzomib versus bortezomib: no longer an ENDEAVOR. <i>Lancet Oncology</i> , The, 2017, 18, 1288-1290.	5.1	9

#	ARTICLE	IF	CITATIONS
109	Primary cardiac lymphoma with central nervous system relapse. Clinical Case Reports (discontinued), 2017, 5, 1454-1458.	0.2	9
110	Could daratumumab be used to treat severe allergy?. Journal of Allergy and Clinical Immunology, 2017, 139, 1677-1678.e3.	1.5	8
111	Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma. HemaSphere, 2020, 4, e413.	1.2	8
112	Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study. Blood, 2019, 134, 1826-1826.	0.6	7
113	Practical Considerations for Antibodies in Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 667-674.	1.8	6
114	Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody-based treatment?. Hematology American Society of Hematology Education Program, 2020, 2020, 259-263.	0.9	6
115	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. Journal of Clinical Oncology, 2018, 36, 8013-8013.	0.8	6
116	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer Journal, 2021, 11, 178.	2.8	6
117	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. Blood Cancer Journal, 2022, 12, 41.	2.8	6
118	Immunotherapy in multiple myeloma: when, where, and for who?. Current Opinion in Oncology, 2020, 32, 664-671.	1.1	5
119	First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. Blood Cancer Journal, 2021, 11, 22.	2.8	5
120	Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia, 2021, 35, 2715-2719.	3.3	5
121	Staphylococcus aureus pericardial abscess presenting as a localized bulge of the heart contour. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 818-819.	0.5	4
122	Oral proteasome inhibitor maintenance for multiple myeloma. Lancet, The, 2019, 393, 204-205.	6.3	4
123	Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies. Molecular Cancer Therapeutics, 2020, 19, 2089-2104.	1.9	3
124	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. Cancer Imaging, 2021, 21, 36.	1.2	3
125	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. Hemato, 2021, 2, 116-130.	0.2	2
126	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Advances in Therapy, 2021, 38, 1328-1341.	1.3	2

#	ARTICLE	IF	CITATIONS
127	A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2016, 34, TPS8072-TPS8072.	0.8	2
128	A Novel In Vivo Animal Model for Human Multiple Myeloma Based on Bioluminescence Imaging of Tumor Cell Growth.. Blood, 2005, 106, 3452-3452.	0.6	2
129	Acute and chronic renal artery stenosis. European Heart Journal, 2010, 31, 14-14.	1.0	1
130	A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, TPS8055-TPS8055.	0.8	1
131	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. Blood. 2019. 134. 5549-5549.	0.6	1
132	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. Frontiers in Oncology, 2020, 10, 607571.	1.3	0
133	A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.. Blood, 2004, 104, 3458-3458.	0.6	0